Edition:
United States

UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

56.50EUR
9 Dec 2016
Change (% chg)

€-2.32 (-3.94%)
Prev Close
€58.82
Open
€59.00
Day's High
€59.25
Day's Low
€54.84
Volume
1,278,729
Avg. Vol
294,282
52-wk High
€85.60
52-wk Low
€54.84

Latest Key Developments (Source: Significant Developments)

UCB Q3 revenue up 7 pct, 2016 guidance confirmed
Tuesday, 25 Oct 2016 01:04am EDT 

UCB SA : Financial outlook 2016 confirmed . Reports 9 month revenue of 3.08 billion euros ($3.35 billion) versus 2.86 billion euros year ago . 9 month Cimzia net sales 933 million euros versus 775 million euros a year ago . 9 month Vimpat net sales 583 million euros versus 495 million euros year ago . 9 month Keppra net sales 541 million euros versus 565 million euros a year ago .9 month Neupro net sales 219 million euros versus 199 million euros a year ago.  Full Article

Evotec signs deal to cooperate with UCB on in vitro pharmacology
Thursday, 20 Oct 2016 01:31am EDT 

Evotec AG : Evotec and UCB sign multi-year CNS pharmacology agreement . Under terms of three-year agreement, evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in cns space .No financial details were disclosed.  Full Article

UCB says Delaware court confirms validity Vimpat patent
Monday, 15 Aug 2016 02:49am EDT 

UCB SA : Announced on Sunday that the Delaware District Court confirmed the validity of U.S. patent RE38,551 related to Vimpat .Decision is currently under seal and will be released following an order from the court.  Full Article

Financiere de Tubize H1 profit at 106.4 million euros
Thursday, 28 Jul 2016 02:14am EDT 

Financiere De Tubize Sa : Dividend received from UCB: 74.9 million euros ($82.94 million) . Decreasing debt from 286.3 million euros at 31 December 2015 to 238.0 million euros at 30 June 2016 .H1 profit (consolidated) of 106.4 million euros.  Full Article

UCB H1 profit of group up at 316 million euros
Thursday, 28 Jul 2016 01:03am EDT 

UCB Sa : Financial outlook 2016 confirmed . H1 gross profit increased to 1.45 billion euros ($497.93 million) (+6 pct, +4 pct cer) . H1 revenue and net sales increased to 2.0 billion euros(+5 pct; +5 pct cer) and 1.9 billion euros(+10 pct; +9 pct cer) respectively driven by continued core product growth . H1 underlying profitability -recurring EBITDA- reached 549 million euros (+18 pct; +11 pct cer) .H1 profit of group was 316 million euros(+9 pct; 0 pct cer) of which 300 million euros is attributable to UCB shareholders and 16 million euros to non-controlling interests.  Full Article

Amgen and UCB submit biologics license application for romosozumab to the FDA
Friday, 22 Jul 2016 01:00am EDT 

Ucb SA : Amgen and UCB submit biologics license application for romosozumab to the FDA .Amgen and UCB plan to present results from frame clinical trial at an upcoming medical congress.  Full Article

UCB's Vimpat gets Japanese approval
Monday, 4 Jul 2016 02:36am EDT 

UCB SA : UCB and Daiichi Sankyo <4568.T> announce Japanese approval of lacosamide (brand name Vimpat) as adjunctive therapy in treatment partial-onset seizures in adult patients with epilepsy . UCB and Daiichi Sankyo will jointly commercialize lacosamide in Japan . ucb will manufacture and supply product; Daiichi Sankyo will manage distribution and book sales in Japan, with both companies promoting lacosamide in Japan .Approval reinforces commitment of both companies to improve lives of people in Japan living with epilepsy.  Full Article

UCB confirms FY 2016 guidance, in line with analysts' estimates
Monday, 25 Apr 2016 01:00am EDT 

UCB SA:Financial outlook 2016 confirmed - UCB expects continued growth.2016 revenue should reach approximately 4.0 - 4.1 billion euros; recurring EBITDA should increase to approximately 970 - 1,010 million.FY 2016 revenue: 4.04 billion euros - Thomson Reuters I/B/E/S.FY 2016 EBITDA: 960.9 million euros - Thomson Reuters I/B/E/S.2016 core earnings per share are expected in range of eur 2.90 - 3.20 based on an expected average of 188 million shares outstanding.  Full Article

UCB announces results from study of Cimzia and Humira
Thursday, 24 Mar 2016 02:00am EDT 

UCB SA:Announces results from first head-to-head study of Cimzia (certolizumab pegol) and Humira (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients.ACR20 responses at three months and achievement of low disease activity at two years were numerically comparable between both agents; primary endpoints for superiority were not met.Safety across two years, including serious adverse events and serious infections, was comparable between both agents.  Full Article

UCB and Amgen announce positive top-line results from phase 3 study of Romosozumab
Monday, 22 Feb 2016 01:00am EST 

UCB SA:Amgen and UCB announce positive top-line results from the phase 3 study of romosozumab in postmenopausal women with osteoporosis.‍Data showed frame met co-primary endpoints.‍Secondary endpoint of reducing incidence of non-vertebral fractures through months 12 and 24 was not met​​.‍UCB and Amgen plan to discuss these results with global regulators in anticipation of a potential filing in 2016.  Full Article

BRIEF-UCB says head-to-head study of Cimzia and Humira did not meet primary endpoints

* The Lancet publishes first head-to-head study of Cimzia (certolizumab pegol) and Humira (adalimumab) in bio-naïve rheumatoid arthritis patients